Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 27;25(12):2177–2190. doi: 10.1093/neuonc/noad134

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)

PMC Copyright notice

Figure 6. — Immunohistochemical analysis of a GBM TMA. (A) Representative immunostaining images showing negative (left panel), uniform strong cytoplasmic and nuclear (middle panel), and heterogenous intratumoral and subcellular distribution of Fatty acid-binding protein 7 (FABP7) (right panel). (B) Magnified images from the squared regions shown in (A). Arrowheads point to FABP7 immunoreactivity in cell nucleus. (C, D) Patient overall survival (OS) curves generated based on FABP7 nuclear (C) and cytoplasmic immunoreactivity (D). (E, F) Patient overall survival curves generated based on nuclear FABP7 immunoreactivity in a patient population under (E) or above (F) the median age of 55. Three to six cores from each tumor on TMA slides were immunostained and scored. HR denotes hazard ratio. Scale bars: 100 μm. (G) Graphical summary of the role of the FABP7-RXRα neurogenic pathway in determining stationary to migratory transition in GSC and tumor progression.